Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A dual approach for targeting LAT1 in cancer: Assay innovation and non-amino acid inhibitor development

Award Number: R16GM166333
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2026
PERIOD OF PERFORMANCE END DATE: 04/30/2030

Group Awards By:

View Award Description

A dual approach for targeting LAT1 in cancer: Assay innovation and non-amino acid inhibitor development - Project summary: Amino acids are absorbed and utilized in the body with the help of dedicated transporters that are localized in the cell membranes. In cancer, the malignant cells often require a larger quantity of essential amino acids to survive, proliferate and metastasize thereby causing poor patient outcomes. Among the various transporters, L-amino acid transporter 1 (LAT1) is specifically overexpressed in many cancer cell types to meet the high demand. In contrast, most normal cells do not express LAT1. Clinically, the high expression of LAT1 has been associated with shorter survival in cancer patients. Thus, LAT1 inhibition is sought as a highly promising anti-cancer approach that can selectively target the malignant cells. However, all LAT1 inhibitors developed to date are based on an amino acid structure that results in toxic side effects and limitations relating to oral administration. Our primary goal is to create LAT1 selective inhibitors that have potent anti-cancer activity with fewer unwanted effects. Our design and development efforts will focus on non-amino acid compounds that inhibit LAT1 through a non-competitive mechanism without significant inhibitory effect on LAT2, LAT3, LAT4 or other transporters. In Aim 1, we will synthesize amino acid analogs that serve as broad LAT substrates that will be used in the development of new fluorescence-based assay systems for compound screening and inhibitor potency determinations. Concurrently, efforts will be dedicated to synthesizing the non-amino acid structures based on a monoterpene glycoside compound described previously in the literature. Aim 2 is focused on establishing stable LAT knock down and LAT over-expressing cancer cell lines to be used for validating the substrate transport activities and for screening of the non-amino compounds for inhibitory action. The data from this aim will reveal the structure activity relationship of the non-amino acid inhibitors. In Aim 3, the inhibitory compounds with the highest LAT1 selectivity will be tested for cellular anti-cancer activity using assays for proliferation, apoptosis, spheroid growth and intracellular signaling alterations.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $144,500 )
2026	2026	BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY	#5 HAIRPIN DRIVE	EDWARDSVILLE	IL	62026	MADISON	USA	Biomedical Research and Research Training	000	1	6/30/2026	NEW	$144,500
														Subtotal = $144,500

Grand Total All Awards = $144,500

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A dual approach for targeting LAT1 in cancer: Assay innovation and non-amino acid inhibitor development

Award Number: R16GM166333

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2026

PERIOD OF PERFORMANCE END DATE: 04/30/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer